Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3NIH 3INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3

Conditions

Carcinoma, Non-Small-Cell Lung 50Ovarian Neoplasms 43Lung Neoplasms 41Fallopian Tube Neoplasms 29Carcinoma, Ovarian Epithelial 28Breast Neoplasms 22Neuroblastoma 18Adenocarcinoma of Lung 17Central Nervous System Neoplasms 16Brenner Tumor 12Endometrial Neoplasms 9Adenocarcinoma, Bronchiolo-Alveolar 9Testicular Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Astrocytoma 8Unspecified Adult Solid Tumor, Protocol Specific 7Triple Negative Breast Neoplasms 7Oligodendroglioma 7Lymphoma, Large B-Cell, Diffuse 7Brain Neoplasms 7Head and Neck Neoplasms 6Teratoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Melanoma 5Medulloblastoma 5Leukemia, Myeloid, Acute 5Gliosarcoma 5Glioblastoma 5Thrombocythemia, Essential 4Testicular Germ Cell Tumor 4

Interventions

Specimen Handling 6Nivolumab 6Magnetic Resonance Spectroscopy 6Platinum 4Cisplatin 41,2-diaminocyclohexaneplatinum II citrate 4Gemcitabine 3Carboplatin 3Ipilimumab 2Immunoglobulin G 2Disulfides 2CTLA-4 Antigen 2Biopsy 2relatlimab 1fluciclovine F-18 1cemiplimab 1cabozantinib 1atezolizumab 1X-Rays 1Transurethral Resection of Bladder 1Radiotherapy 1Radiation 1Phantoms, Imaging 1Docetaxel 1Cetuximab 1Bevacizumab 1(225)Ac-DOTA-c(RGDyK) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Nasopharyngeal Carcinoma × Carboplatin × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06029270 2026-06-03

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
156 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT04458909 2025-10-03

Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

National Cancer Institute (NCI)

Phase 3 Terminated
15 enrolled 17 charts
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡